Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Brain tumor, adult: General and other
Stage/Subtype:  recurrent adult brain tumor
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 119 for your search:
Start Over
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 22 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EF-19, NCT01756729
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000654697, ECOG-E3F05, E3F05, NCT00978458
A Study of the Efficacy and Safety of Nivolumab vs Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients at Different Stages of Treatment (CheckMate 143)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA209-143, 2013-003738-34, NCT02017717
Combination Chemotherapy With BBBD Followed By Sodium Thiosulfate in Treating Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: OHSU-2868, P30CA069533, 8507, SOL-04058-L, 2868, OHSU-8507, OHSU-SOL-04058-L, NCT00303849
A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: COZ-SIU 10-002-1, NCT01128218
A Study of a Retroviral Replicating Vector Administered to Subjects With Recurrent Malignant Glioma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: Tg 511-08-01, NCT01156584
Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VB-111-122, NCT01260506
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 14-353, NCT01269853
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI CNS 13, NCT01349660
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BTTC09-01, NCI-2011-03056, NCT01434602
CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110266, 11-C-0266, NCT01454596
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: DLM-10-001, NCT01478178
Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HCI55264, NCT01580969
Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 3 and over
Sponsor: Other
Protocol IDs: 2011-0844, NCI-2012-00849, NCT01596127
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01989, CDR0000737109, NCCTG-N1174, N1174, U10CA180821, U10CA025224, NCT01648348
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CINC280X2204, NCT01870726
A Phase I/II Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: VICC NEU 1308, NCT01891747
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioblastoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CTRC 12-02, NCT01906385
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TPI-287-17, NCT01933815
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CBKM120E2102, 2013-003129-27, NCT01934361
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: NLG2102, NCT02052648
Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AG221-C-003, NCT02273739
PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 3 to 30
Sponsor: NCI
Protocol IDs: 150093, 15-C-0093, NCT02390752
Treating Patients With High-Grade Glioma With Intra-Arterial (IA) Carboplatin-based Chemotherapy, With or Without Sodium Thiosulfate
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: OHSU-922, ONC-02059-L, 922, 7328, OHSU-7328, OHSU-ONC-02059-L, CASE-CCF-6385, NCT00075387
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EMD 121974-009, DUMC-6486-04-10R0, NCT00093964
Start Over